Description

Each Owens Peptide Solutions vial provides 30mg of lyophilized Trizepatide for qualified scientific research. The peptide is designed as a dual agonist of the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor.

Research Use Disclaimer:

For laboratory and research use only. Not intended for human or animal consumption, medical use, diagnostic use, veterinary use, or therapeutic application.

Its structure incorporates a fatty diacid component associated with reversible albumin binding and greater stability in experimental systems. These characteristics allow researchers to study prolonged receptor interaction, dual incretin signaling, and peptide pharmacology under controlled laboratory conditions.

Preclinical investigations have examined glucose-dependent cellular responses, insulin and glucagon pathway activity, receptor binding, and broader metabolic signaling. Findings remain dependent on the selected model and should not be interpreted as confirmed clinical outcomes.